基于代谢的肝病靶标确证及原创肝病药物发现
(1) 肝病药靶确证和药物发现 (代谢调控；转录因子；基因治疗；天然产物)
(2) 肝癌化疗耐药机理及增敏策略（内源代谢；肠道菌；程序性细胞死亡）
☆ 特别提醒 ☆ ：
2026年硕士招生专业：药理学（学硕）、药学/新药临床前评价 （专硕）
2026年博士招生专业：药理学
本课题组长期招聘博士后：https://rcb.cpu.edu.cn/05/7b/c12016a198011/page.htm
欢迎致力于肝病药理研究的广大学子报考！

1.学术获奖
NIH: Fellows Award for Research Excellence (FARE) competition, 2022, 排名1/1
NCI/CCR: Travel Award- Outstanding Oral Presentation, 2023，排名1/1
Acta Pharmaceutica Sinica B: 2021 High Impact Paper Award, 2021, 排名1/1
NIH: Outstanding GPP Graduation Research Award, 2016, 排名1/1
2.代表性科研成果
(1) 揭示核受体PPARα及代谢酶SCD1等在肝肠组织中对脂肪肝病的差异调控作用和机理
(2) 阐明转录因子CEBPα在肝细胞中通过抑制OPN转录和释放来缓解OPN对临近肝星型细胞的激活从而缓解肝纤维化
(3) 从代谢角度出发揭示醉茄素A及甘草酸等天然产物改善肝病的作用和机理

(1) Xia Y#, Zhang Y#, Zhang Z#, Yan N, Sawaswong V, Sun L, Guo W, Wang P, Krausz KW, Gavrilova O, Ntambi JM, Hao H, Yan T*, Gonzalez FJ*. Intestinal stearoyl-coenzyme A desaturase-inhibition improves obesity-associated metabolic disorders. Acta Pharm Sin B, 2025, 15(2):892-908. (IF=14.5)
(2) Yan T, Yan N, Xia Y, Sawaswong V, Zhu X, Dias HB, Aibara D, Takahashi S, Hamada K, Saito Y, Li G, Liu H, Yan H, Velenosi TJ, Krausz KW, Huang J, Kimura S, Rotman Y, Qu A*, Hao H*, Gonzalez FJ*. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression. J Clin Invest, 2024, 134(7):e166731 (IF=15.9)
(3) Yan T#, Luo Y#, Yan N, Hamada K, Zhao N, Xia Y, Wang P, Zhao C, Qi D, Yang S, Sun L, Cai J, Wang Q, Jiang C, Gavrilova O, Krausz KW, Patel DP, Yu X, Wu X, Hao H, Liu W*, Qu A*, Gonzalez FJ*. Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology, 2023, 77(1):239-255 (IF=13.5)
(4) Zhang Y#, Yan T#*, Wang T, Liu X, Hamada K, Sun D, Sun Y, Yang Y, Wang J, Takahashi S, Wang Q, Krausz KW, Jiang C, Xie C, Yang X*, Gonzalez FJ*. Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity. Acta Pharm Sin B, 2022, 12(5):2224-2238 (IF=14.5)
(5) Hamada K#, Wang P#, Xia Y#, Yan N, Takahashi S, Krausz KW, Hao H, Yan T*, Gonzalez FJ*. Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis. Food Chem Toxicol, 2022, 160:112807 (IF=4.3)
(6) Yan T#, Luo Y#, Xia Y, Hamada K, Wang Q, Yan N, Krausz KW, Ward JM, Hao H, Wang P*, Gonzalez FJ*. St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NFκB antagonism. FASEB J, 2021, 35(11):e21968 (IF=5.8)
(7) Yagai T#, Yan T#, Luo Y#, Takahashi S, Aibara D, Kim D, Brocker CN, Levi M, Motohashi H, Gonzalez FJ*. Feedback repression of PPARα signaling by Let-7 microRNA. Cell Rep, 2021, 36(6):109506 (IF=10.0)
(8) Yan T#, Yan N#, Wang H, Yagai T, Luo Y, Takahashi S, Zhao M, Krausz KW, Wang G*, Hao H*, Gonzalez FJ*. FXR-Deoxycholic Acid-TNF-α Axis Modulates Acetaminophen-Induced Hepatotoxicity. Toxicol Sci, 2021, 181(2):273-284 (IF=4.1) (9) Xia Y#, Wang P#, Yan N, Gonzalez FJ*, Yan T*. Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3. Cell Death Dis, 2021, 12(2):174 (IF=9.7)
(10) Yan T*, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ*. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B, 2020, 10(1):3-18 (IF=11.6)

课题组长
颜婷婷 教授
博士后
范辉
博士研究生
颜娜娜(2021级)
代梦格 （2024级）
李开颖(2025级)
硕士研究生
聂亮亮(2024级)
杨影 （2024级）
许熙（2025级）
庄彩梦（2025级）
施雨婕（2025级）
陈文慧（2025级）